ANIX Key Statistics, Chart & Performance
The current stock price of ANIX is 3.18 USD. In the past month the price decreased by -30.72%. In the past year, price increased by 33.61%.
ANIX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.43 | 407.98B | ||
| AMGN | AMGEN INC | 15.07 | 177.50B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.49 | 116.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.34 | 82.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 782 | 52.69B | ||
| INSM | INSMED INC | N/A | 37.61B | ||
| NTRA | NATERA INC | N/A | 31.92B | ||
| BIIB | BIOGEN INC | 10.56 | 25.94B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.06 | 21.65B | ||
| INCY | INCYTE CORP | 15.47 | 19.49B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About ANIX
Company Profile
Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. The company is headquartered in San Jose, California and currently employs 5 full-time employees. The firm's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The firm's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The firm is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.
Company Info
ANIXA BIOSCIENCES INC
3150 Almaden Expy Ste 250
San Jose CALIFORNIA 95118 US
CEO: Amit Kumar
Employees: 5
Phone: 14087089808
ANIXA BIOSCIENCES INC / ANIX FAQ
Can you describe the business of ANIXA BIOSCIENCES INC?
Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. The company is headquartered in San Jose, California and currently employs 5 full-time employees. The firm's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The firm's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The firm is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.
What is the current price of ANIX stock?
The current stock price of ANIX is 3.18 USD. The price decreased by -0.63% in the last trading session.
What is the dividend status of ANIXA BIOSCIENCES INC?
ANIX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANIX stock?
ANIX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about ANIXA BIOSCIENCES INC (ANIX) stock?
10 analysts have analysed ANIX and the average price target is 10.2 USD. This implies a price increase of 220.75% is expected in the next year compared to the current price of 3.18.
What is ANIXA BIOSCIENCES INC worth?
ANIXA BIOSCIENCES INC (ANIX) has a market capitalization of 104.69M USD. This makes ANIX a Micro Cap stock.
What is the Short Interest ratio of ANIXA BIOSCIENCES INC (ANIX) stock?
The outstanding short interest for ANIXA BIOSCIENCES INC (ANIX) is 1.85% of its float.
ANIX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ANIX. When comparing the yearly performance of all stocks, ANIX is one of the better performing stocks in the market, outperforming 81.14% of all stocks.
ANIX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ANIX. While ANIX has a great health rating, there are worries on its profitability.
ANIX Financial Highlights
Over the last trailing twelve months ANIX reported a non-GAAP Earnings per Share(EPS) of -0.35. The EPS increased by 10.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.97% | ||
| ROE | -66.98% | ||
| Debt/Equity | 0 |
ANIX Forecast & Estimates
10 analysts have analysed ANIX and the average price target is 10.2 USD. This implies a price increase of 220.75% is expected in the next year compared to the current price of 3.18.